SUMMARY Preliminary observations on the effect of D(-)penicillamine on chronic antigen-induced experimental arthritis in rabbits are reported. Daily oral administration of penicillamine, at a dose equivalent to that usually administered to rheumatoid arthritis patients, diminished the arthritis in 2 out of 3 animals as assessed by both measurement of joint circumference and histological examination.
Although D(-)penicillamine has been shown to be of therapeutic value in the treatment of rheumatoid arthritis (Multicentre Trial Group, 1973 ), its precise mode of action in this condition remains unclear. Unfortunately, any attempt to understand the basis ofthe clinical effects of penicillamine at the molecular or cellular level is complicated by the usual practice of its co-administration with known anti-inflammatory drugs such as corticosertoids and aspirin. This problem may be overcome by investigation of the influence of penicillamine on experimental models of arthritis in animals. However, previous studies (Liyanage and Currey, 1972) have shown that this drug failed to affect adjuvant arthritis in rats. We report now the findings from a preliminary investigation of the effects of penicillamine on the rabbit experimental arthritis model of Dumonde and Glynn (1962) where the compound was observed to bring about an impressive reduction in joint swelling in 2 out of 3 animals which survived the study.
Experimental arthritis was induced in New Zealand White/Californian cross rabbits, using ovalbumin as antigen, as described by Consden et al. (1971) . The animals were immunized by two subcutaneous injections of ovalbumin in Freund's complete adjuvant, and challenged 6 weeks later by intraarticular injection of the antigen into the right knee (the left knee being injected with saline as a control), after the existence of delayed hypersensitivity to the antigen had been established by skin testing. Each rabbit produced an arthritic response in the antigenAccepted for publication November 11, 1976 Correspondence to Dr. D. R. Stanworth injected joint, which continued through an acute phase into a chronic phase. At this state (ie 115 days after intra-articular injection) there appeared to be some variation between animals in the degree of inflammation of the antigen-injected joint, as judged by increase in joint circumference (determined by tape measurement). Consequently, the animals were paired according to the circumference of the antigeninjected joint; one animal of each pair being treated with 60 mg D(-)penicillamine (DistamineTm) per day: ie 15 mg per kg body weight, a dose equivalent to that usually received by human rhematoid arthritis patients. The drug was administered orally in gelatin capsule form, by expulsion from a tube connected to the end of a syringe. One animal failed to survive penicillamine treatment; of the 3 remaining animals receiving oral penicillamine, 2 appeared to respond to the drug after 4 and 8 weeks of treatment respectively as judged by a marked decrease in the circumference of the antigen-injected knee joint relative to the salineinjected (control) knee (Fig.) . In contrast, no decrease in the degree of swelling of the antigeninjected knee joints of the control (ie no penicillamine) animals was observed. The experiment was continued until 325 days after intra-articular injection, when all the animals were sacrificed and the knee joints examined.
Post-mortem histological examination of the antigen-injected joints of the control (no penicillamine) animals showed considerable inflammation as judged by villous hyperplasia and infiltration of plasma cells and lymphocytes into the synvoium.
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